CLOs on the Move

AbbVie

www.abbvie.com

 
At AbbVie, we believe the world needs new approaches to addressing today`s health issues — from life-threatening illness to chronic conditions. We combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people`s lives. With 28,000+ employees and medicines in over 170 countries, AbbVie is uniting the best of pharma and the boldness of biotech, to innovate end-to-end approaches that make a real difference in people`s lives.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.abbvie.com
  • 1 North Waukegan Road
    North Chicago, IL USA 60064
  • Phone: 847.932.7900

Executives

Name Title Contact Details
Arya Sadeghi
 Senior Counsel Profile
Laura Brake
 Associate General Counsel Profile
Matt Bennett
 Head of Sales, Teliso-V Profile
Paul Hammond
 Associate General Counsel Profile
Ying Deng
 Senior Associate General Counsel, Global Profile

Similar Companies

Meier Clinics

Meier Clinics provides Christian counseling for those struggling with depression, anxiety, marriage issues, grief, ADD or ADHD, bipolar, and a variety of other issues.

Keeps

Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.

Trinity Biotech

Trinity Biotech specialises in the development, manufacture and marketing of diagnostic test kits.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.

Vision RT

Vision RT is the inventor of Surface Guided Radiation Therapy (SGRT) and produces a range of innovative solutions to improve radiation therapy.